Compare DexCom, Inc. (DXCM) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Uranium Energy Corp — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Uranium Energy Corp trades at $9.19 (market cap $4.53B). The key difference: DexCom, Inc. is far larger — about 7× Uranium Energy Corp's market cap, and DexCom, Inc. is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Uranium Energy Corp for 37 Days on average.
| DXCM | UEC | |
|---|---|---|
Market Cap | $31.86B | $4.53B |
Volume | 3,607,070 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $92.34 | $20.14 |
52-Week Low | $54.84 | $9.04 |
Typical Hold Time | 62 Days | 37 Days |
Enterprise Value | $31.32B | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Uranium Energy (UEC) trades at $9.19, down 2.96% in the last session. The stock shows bearish technical signals with negative earnings momentum, posting losses in recent quarters despite revenue growth. The company is expanding its US uranium mining operations with two active mines, benefiting from increased government demand for domestic nuclear fuel. Analyst sentiment remains overwhelmingly positive with 87.5% buy ratings and a $16.06 consensus price target, though fundamental metrics show significant losses with a -368.62% net income margin.
UEC presents a high-risk, high-reward opportunity with strong Wall Street support but concerning financials. The bullish case hinges on nuclear energy expansion and domestic uranium demand growth, while risks include sustained operational losses, unproven production sustainability, and heavy reliance on financing activities. Current valuation appears stretched given negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
